TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic Phase 1 ...
Company expects to initiate a randomized, double-blind, placebo-controlled, adaptive Phase 2 field study in the first half of 2027, pending FDA clearance BERKELEY HEIGHTS, N.J., March 31, 2026 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results